Retatrutide Triumph 4 28.7 Percent Weight Loss December 2025 Results

Eli Lilly's retatrutide triumph 4 28.7 percent weight loss December 2025 results have made headlines in obesity treatment.[1] In the Phase 3 TRIUMPH-4 trial, patients with obesity and knee osteoarthritis achieved an average 28.7% body weight reduction on the 12 mg dose after 68 weeks, far surpassing placebo.[1][2] These findings also showed major improvements in knee pain and physical function, signaling a potential game-changer for those with weight-related joint issues.[1]

Introduction to Retatrutide Triumph 4 28.7 Percent Weight Loss December 2025 Results

What Are the Headline Findings from TRIUMPH-4?

The retatrutide triumph 4 28.7 percent weight loss December 2025 results, announced on December 11, 2025, highlight exceptional efficacy.[1] At the highest 12 mg dose, participants lost 28.7% of their body weight on average, equivalent to up to 71.2 pounds for many.[1] This beat the 9 mg dose's 26.4% loss and placebo's mere 2.1%, meeting the primary endpoint with strong statistical significance.[1]

Beyond weight, the trial excelled in knee osteoarthritis outcomes. Retatrutide users saw a 75% improvement in WOMAC pain scores, with about 1 in 8 becoming completely pain-free.[1] Cardiovascular markers like cholesterol, blood pressure, and inflammation (hsCRP) also improved, especially at 12 mg.[1]

These topline data come from a rigorous Phase 3 study, but full details await peer-reviewed publication.[1] Early expert reactions praise the "powerful effect" on weight, pain, and function, per Lilly's Kenneth Custer.[1]

Why These Results Matter for Obesity and Knee Osteoarthritis Treatment

Obesity often worsens knee osteoarthritis, creating a cycle of pain and limited mobility. The retatrutide triumph 4 28.7 percent weight loss December 2025 results break this cycle by targeting both issues simultaneously. Patients not only shed significant weight but also regained physical function, which could reduce reliance on surgeries or pain meds.

For the millions affected, this means hope for non-diabetic overweight individuals with knee OA. Unlike prior drugs, retatrutide's triple action delivered higher weight loss thresholds—many hit 25%, 30%, or even 35% reductions, rare in earlier trials.[1] This could shift treatment paradigms, emphasizing weight management as key to joint health.

As part of Lilly's TRIUMPH program, these findings build momentum for broader approvals.[1] They underscore retatrutide's potential in comorbidity-driven obesity care.

What Is Retatrutide and How Does It Work?

Triple Agonist Mechanism: GIP, GLP-1, and Glucagon Receptors

Retatrutide is a first-in-class triple agonist, mimicking three key hormones: GIP, GLP-1, and glucagon.[3] GLP-1 curbs appetite and slows digestion, like drugs such as semaglutide. GIP boosts insulin response, while glucagon burns fat and preserves muscle.[3]

This combo drives superior weight loss by enhancing fullness, energy use, and fat metabolism. In trials, it led to the retatrutide triumph 4 28.7 percent weight loss December 2025 results without major muscle loss.[1] Administered weekly via subcutaneous injection, it fits busy lifestyles.[2]

Development by Eli Lilly and Administration Details

Eli Lilly developed retatrutide (LY3437943) to outpace single or dual agonists.[1] Dosing starts low and titrates up to avoid side effects, reaching 9 mg or 12 mg in TRIUMPH-4.[1] It's used alongside diet and exercise for best results.[2]

The drug's profile suits chronic obesity management. Lilly's investment in the TRIUMPH program tests it across indications, from plain obesity to complications like OA.[1]

Role in the Broader TRIUMPH Phase 3 Program

TRIUMPH includes four basket trials with over 5,800 participants, covering obesity, type 2 diabetes, sleep apnea, knee OA, and heart disease.[1] TRIUMPH-4 focuses on knee OA, but results inform the pack.[1] Seven more readouts, including the retatrutide 4mg maintenance dose in TRIUMPH trials, are due in 2026.[1]

This program accelerates data collection, positioning retatrutide for potential multi-indication approvals.

TRIUMPH-4 Clinical Trial Design and Patient Population

Trial Overview: NCT05931367, Phase 3, 68 Weeks

TRIUMPH-4 (NCT05931367) is a double-blind, randomized, multicenter Phase 3 trial lasting 68 weeks.[2] It compared retatrutide at 9 mg and 12 mg against placebo in adults with obesity or overweight plus knee OA, no diabetes.[1][2] Primary endpoints: percent body weight change and WOMAC pain score.[1][2]

ClinicalTrials.gov details the controlled type I error and robust design.[2] Topline retatrutide triumph 4 28.7 percent weight loss December 2025 results confirmed endpoint hits.[1]

Doses Tested: 9 mg vs 12 mg vs Placebo

Highest investigational doses were tested: gradual titration to 9 mg or 12 mg weekly.[1] Placebo mimicked injections. This setup isolated retatrutide's effects adjunct to lifestyle changes.[2]

Higher doses drove better outcomes, with 12 mg shining in weight and pain metrics.[1]

Target Population: Obesity/Overweight with Knee OA (No Diabetes)

Participants had BMI ≥27 kg/m² and symptomatic knee OA, many with baseline BMI ≥35.[1][2] Exclusion of diabetes honed focus on obesity-OA link.[2] This group faces high disability risks, making results highly relevant.

Efficacy Results: 28.7% Weight Loss and Beyond

Primary Endpoint: Average 28.7% Body Weight Loss at 12 mg Dose

The standout from retatrutide triumph 4 28.7 percent weight loss December 2025 results: 28.7% mean reduction at 12 mg (placebo-adjusted 26.6%).[1] This topped analyst predictions of 20-23%.[1] Even at 9 mg, loss reached 26.4%.[1]

Weight plateaued meaningfully, with sustained benefits over 68 weeks.[1]

Weight Loss Breakdown: 9 mg Dose, Placebo Comparison, and High Achievers (≥25%, ≥30%, ≥35%)

Here's a quick comparison table of weight loss outcomes:

Dose	Average Weight Loss	Placebo-Adjusted	High Achievers (≥25/30/35%)
12 mg	28.7%[1]	26.6%[1]	High proportions[1]
9 mg	26.4%[1]	N/A	Notable[1]
Placebo	2.1%[1]	-	Low

These thresholds, uncommon before, show retatrutide's potency in tough populations.[1]

Knee Pain Reduction: 75% WOMAC Improvement and 12.5% Pain-Free

Key secondary: 75% WOMAC pain drop vs. placebo, doubling semaglutide's prior 42% in similar settings.[1] See retatrutide vs semaglutide weight loss comparison. 12.5% achieved zero pain.[1] Function scores rose, aiding daily life.

Secondary Benefits: Physical Function, CV Risk Markers (Cholesterol, BP, hsCRP)

Physical function improved markedly.[1] At 12 mg:

• Lower non-HDL cholesterol and triglycerides.[1]
• Reduced systolic BP and hsCRP (inflammation marker).[1]

These cardiometabolic gains enhance retatrutide's value.[1] Eli Lilly Investor Release[1]

Safety Data and Side Effects from TRIUMPH-4

Common Adverse Events: GI Issues (Nausea, Diarrhea, Constipation)

GI effects dominated, typical of incretin drugs: nausea, diarrhea, constipation, appetite drop.[1] Most were mild-moderate, early, and dose-dependent. Heart rate rose transiently, managed by titration.

Discontinuation Rates: 12-18% at Higher Doses, BMI ≥35 Correlation

Discontinuations due to AEs: 12.1-18.2% (9/12 mg) vs. 4-4.8% placebo.[1] For BMI ≥35: 8.8-12.1% drug vs. 4.8% placebo.[1] See deeper analysis on retatrutide Phase 3 discontinuation rates and BMI correlation.

Linked to rapid weight loss in heavier patients.

Emerging Signal: Dysesthesia and Other Concerns

A new signal: dysesthesia (abnormal touch sensation).[1] Impact unclear, pending full data. No major red flags otherwise.

Learn more on dysesthesia side effect in retatrutide trials.

Overall Safety Profile Compared to Incretin Class Drugs

Consistent with GLP-1/GIP class, but higher discontinuations note caution.[1] Benefits outweighed risks in this population. Full profile in upcoming publications.[1]

Regulatory Status and FDA Approval Timeline

Current Status: Investigational, Topline December 11, 2025

Retatrutide remains investigational—no FDA approval as of retatrutide triumph 4 28.7 percent weight loss December 2025 results.[1] TRIUMPH-4 topline positive, but detailed data pending medical meetings.[1]

Check is retatrutide FDA approved yet?.

Next Steps: Full Data Publication, Additional TRIUMPH Readouts in 2026

Full TRIUMPH-4 results for peer review.[1] Seven more Phase 3 readouts in 2026 across indications.[1]

Approval Projections: Analyst Forecasts for 2027

Analysts eye 2027 approval post-TRIUMPH completion.[1] Track via latest retatrutide FDA approval tracker.

TRIUMPH-4 in Context: Comparisons and Future Implications

How It Stacks Up Against Semaglutide and Other GLP-1s

Retatrutide's 28.7% loss tops semaglutide's ~15-20% in similar durations.[1][3] Pain relief (75%) doubled semaglutide's 42%.[1] Triple agonism gives edge.[3]

Metric	Retatrutide (12 mg)	Semaglutide (est.)
Weight Loss	28.7%[1]	15-20%[3]
Pain Reduction	75%[1]	42%[1]
High Loss Achievers	High (≥35%)[1]	Lower

Implications for Obesity with Comorbidities like Knee OA

Transforms care for obesity-OA patients, potentially delaying joint replacements. Weight loss drives pain relief, function gains.

Maintenance Dosing and Broader TRIUMPH Trials

Other TRIUMPH arms test 4 mg maintenance.[1] Supports long-term use.

Conclusion: What the Retatrutide Triumph 4 Results Mean for Patients

Key Takeaways on Efficacy, Safety, and Availability

The retatrutide triumph 4 28.7 percent weight loss December 2025 results mark a milestone, with 28.7% average weight loss at 12 mg, 75% knee pain reduction via WOMAC scores, and cardiometabolic improvements like lower cholesterol and blood pressure.[1] Safety shows familiar GI side effects with higher discontinuation rates (12-18%) in those with BMI ≥35, plus a dysesthesia signal to watch.[1] Overall, benefits appear strong for obesity and knee OA patients, though full data will clarify long-term effects.[1]

Key stats recap:

• Weight loss: 28.7% (12 mg) vs. 2.1% placebo—up to 71.2 lbs.[1]
• Pain relief: 75% WOMAC improvement; 12.5% pain-free.[1]
• High achievers: Many reached ≥25%, ≥30%, ≥35% loss.[1]
• Status: Investigational; 2027 approval eyed.[1]

Expert quote: "These results demonstrate a powerful effect on body weight, pain, and physical function," said Kenneth Custer, Lilly's Executive VP.[1] Hypothetical patient perspective: "After years of knee pain limiting my walks, losing 65 pounds on retatrutide let me play with my grandkids pain-free," shares a trial-like participant.

Stay Updated on Full Results and Approval Progress

Full TRIUMPH-4 details and seven more 2026 readouts will shape retatrutide's path.[1] Availability details at retatrutide availability and expected release date. Subscribe for updates on approvals, or consult your doctor about current GLP-1 options like semaglutide while awaiting this potential breakthrough. The retatrutide triumph 4 28.7 percent weight loss December 2025 results offer real hope—stay informed as data unfolds.

References

1. Eli Lilly TRIUMPH-4 Topline Results Press Release
   
2. ClinicalTrials.gov: TRIUMPH-4 Trial Record (NCT05931367)
   
3. NEJM: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
   
4. Eli Lilly Phase 2 Retatrutide Results Press Release